Overview of Febrilex

What is Febrilex? Defining its Core Purpose and Composition

Property	Description
Active Ingredient(s)	Paracetamol (Acetaminophen)
Common Forms	Tablet, Syrup
Pharmacological Class	Analgesic and Antipyretic (often combined)
General Purpose	Symptomatic treatment of cold, flu-like symptoms, fever, and associated pain
Origin	Synthetic compound

What is Febrilex and Its Pharmacological Identity?

Febrilex is a trademarked medicinal product, typically formulated as a combination preparation designed for comprehensive relief of cold and flu symptoms, distinguishing its market position from single-ingredient pain relievers. Its primary therapeutic component is the widely utilized active substance, Paracetamol (Acetaminophen, APAP), which functions as a core analgesic and antipyretic. This combination status means the product is designed to address multiple simultaneous symptoms commonly seen in upper respiratory tract conditions.

Composition and Available Forms of Febrilex

The final composition of Febrilex is generally a multi-ingredient product, which pairs Paracetamol with other active substances, such as an antihistamine (Chlorphenamine Maleate) and a nasal decongestant (Phenylephrine Hydrochloride), forming its distinct therapeutic profile. The drug is supplied in high-level dosage forms including tablets for adult consumption and syrups specifically formulated for pediatric use (marketed as FEBRILEX Junior). This variety in form and specialized flavoring facilitates flexible and appropriate administration via the oral route across different patient age groups.

General Purpose and Core Symptomatic Relief

The general purpose of Febrilex is concentrated on delivering targeted symptomatic relief from the discomfort associated with viral illnesses or allergic conditions. The Paracetamol component specifically works to mitigate mild-to-moderate pain and regulate the hypothalamic heat-regulating center to reduce fever. The inclusion of the other components aims to concurrently relieve secondary cold symptoms like sneezing, running nose, and nasal congestion, providing a multi-action approach to managing the general malaise that accompanies a typical flu-like presentation. The use of Paracetamol as a core antipyretic is a standard element of its therapeutic application.

Therapeutic Uses of Febrilex

What Febrilex Treats: Main Uses and Benefits

Febrilex is commonly used in situations involving symptoms related to physical discomfort, applied across domains where additional symptomatic support is needed, for symptom groups that frequently cluster during conditions associated with acute or disruptive episodes and conditions involving inflammatory or irritative processes. It is generally applied when short-term symptomatic assistance is needed to improve patient comfort.

The medication is considered relevant for the symptomatic management of fever (elevated body temperature), headache, body aches, sore throat, nasal congestion, runny nose, and sneezing. These active ingredient combinations are used for the symptomatic relief of cold, flu, and allergy symptoms.

The core therapeutic benefit provides support that helps ease the overall symptom burden, and may contribute to improved day-to-day comfort during symptomatic periods. This application is relevant in scenarios where additional management of discomfort is required, as one common goal of this type of supportive care is “to help address symptoms related to heightened physiological activity.”

Quick Fact: Relief for Cluster Symptoms

The product is applied across domains where additional symptomatic support is needed, used for managing symptom clusters that interfere with daily comfort.

Regulatory References

ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL tablet label information

Eligibility and Restrictions for Use

Who can and cannot use Febrilex?

The eligibility profile for Febrilex is strictly governed by regulatory classifications, defining which populations are allowed, restricted, or prohibited from using the medicine. Use is defined across specific population, age, and comorbidity domains.

Contraindicated Populations (Must Not Use)

Condition / Status	Restriction
Drug History	Contraindicated in patients currently taking, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI).
Allergy	Contraindicated for individuals with a known hypersensitivity to Acetaminophen, Chlorphenamine, Phenylephrine, or any components.

Age-Related Eligibility

Adults and Children 12 years of age and over: Use is permitted under standard labeled conditions.
Children 4 to 12 years of age: Use is restricted and requires consultation with a health professional.
Children under 4 years of age: Use is explicitly prohibited by regulatory authorities.

Condition-Specific Restrictions (Use with Caution)

Consultation with a health professional is required if a patient has pre-existing conditions, including:

Organ Function: Severe liver disease or kidney disease.
Cardiovascular: High blood pressure or heart disease.
Other: Glaucoma, thyroid disease, or trouble urinating due to an enlarged prostate gland.

Pregnancy and Lactation Status

The official labeling advises individuals who are pregnant, trying to become pregnant, or breastfeeding to ask a health professional before use. Additionally, the medicine must not be used with any other product containing Acetaminophen/Paracetamol to avoid the risk of severe liver damage.

What should I know about interactions with other medicines?

Febrilex Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Febrilex (Paracetamol, Chlorphenamine Maleate, Phenylephrine Hydrochloride) based on regulatory prescribing information.

Official Regulatory Interaction Constraints

Classification	Interacting Substance/Class	Official Regulatory Statement
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Use is prohibited due to the risk of a strong adrenergic reaction. This prohibition extends for two weeks following the discontinuation of MAOI treatment.
Contraindicated Combination	Other Paracetamol-containing Products	Avoidance is required to prevent the risk of accidental Paracetamol overdose.
Risk of Potentiation	Central Nervous System (CNS) Depressants	Co-administration is noted to potentiate sedative effects due to the Chlorphenamine component.
Risk of Toxicity	Alcohol (Ethanol)	Specifically documented to increase the risk of Paracetamol-related hepatotoxicity by lowering the liver toxicity threshold and increasing sedation.
Risk of Toxicity	Potent Hepatic Enzyme Inducers	Substances like Rifampicin or certain anti-convulsants are cited as risk factors for increasing the potential for Paracetamol-induced liver damage.
Timing Separation Rule	Colestyramine	To minimize the reduction in Paracetamol absorption, this product should be administered 1 hour prior or 4 hours after Colestyramine.

Effects on Drug Exposure

Certain substances affect the concentration or elimination of Febrilex components. Probenecid is noted to decrease the clearance of Paracetamol, while agents like Metoclopramide and Domperidone may increase the speed of Paracetamol absorption. Additionally, prolonged, regular use of Paracetamol with Warfarin may enhance the anticoagulant effect, which requires appropriate monitoring.

Population-Specific Notes

The prescribing information notes that individuals with chronic alcoholism, chronic malnutrition, or existing liver impairment may have a lowered liver toxicity threshold for the Paracetamol component.

Mechanism of Action

How Febrilex Works

Febrilex acts through a dual mechanism, engaging two distinct signaling pathways.

Modulating Central Temperature Control

This mechanism involves the targeted inhibition of cyclooxygenase (COX) enzymes primarily within the hypothalamus, the brain's thermoregulatory center. By restricting the synthesis of specific prostaglandins ( PGE2), the drug prevents the signaling sequence that typically elevates the body's temperature set point. This action results in a physiological consequence that includes increased heat dissipation by the body's thermoregulatory mechanisms.

Blocking Histamine Receptor Activity

The second mechanism engages in competitive antagonism at histamine H1 receptors across central and peripheral tissues. By blocking these receptors, Febrilex prevents the downstream effects of histamine on cellular function. This mechanism results in stabilized vascular permeability and decreased activity of certain secretory glands, leading to a physiological consequence of decreased fluid leakage and glandular output.

Dosage and Administration Information

Administration Guidelines

Febrilex is administered via the oral route, available in both tablet and oral liquid forms. Standard usage involves dose constraints and precise timing, ensuring that a minimum of four hours must separate each successive dose. This required interval is a key component for maintaining the usage schedule.

For adults and adolescents 12 years of age and older, the frequency involves taking a unit dose, such as one tablet (containing the 500 mg Paracetamol component), every four to six hours as required. The overarching restriction is that the total daily intake of the Paracetamol component, derived from all sources, must not exceed 4000 mg in a 24-hour period. This limit dictates the maximum number of doses that may be administered in one day.

Contextual instructions for intake state that the medicine can be taken with or without food. If the tablet formulation is used, it is swallowed whole with water and should not be crushed, chewed, or dissolved. Use of the medicine is designated for a short duration, typically not to exceed three to seven days for managing symptoms. Furthermore, it is not to be taken simultaneously with any other product containing Paracetamol.

Recent Clinical Evidence

Febrilex: Recent Clinical Evidence

The research for Febrilex's combination of active ingredients (Paracetamol, Chlorphenamine, and Phenylephrine) focuses on exploring how symptoms change over time in individuals experiencing symptoms associated with the common cold or flu-like syndromes. This summary describes the structure and scope of the evidence research examined and monitored.

Evidence for Symptomatic Relief of Cold and Flu-like Syndromes

The evidence was studied for exploring the study of multiple outcomes related to physical discomfort that often cluster together during acute illnesses. Research focused on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate fixed-dose combinations of this type.

These trials were observed in study participants, typically adults (18 to 65 years of age), who presented with conditions associated with acute or disruptive episodes. The primary measurement used by researchers was the Total Symptom Score (TSS), which is used in research exploring how acute or episodic symptoms (such as fever, pain, and congestion) change over time. Evidence on these types of combinations is available within the broader evidence landscape concerning the outcomes related to systemic or functional imbalance that happen during a cold.

Duration of Studies and Follow-up Timeframes

The research was evaluated in settings focusing on short-term symptom changes. The primary efficacy assessments were conducted during periods of increased symptom activity and typically focused on outcomes measured over 48 to 72 hours. Because the follow-up durations were limited to the acute phase of illness, the evidence provides limited information for long-term outcomes or how systemic or functional imbalance persists beyond the acute treatment window. The research did not monitor patterns related to a change in the overall number of days an individual experienced the cold or flu-like syndrome.

Evidence in Different Age Groups and Research Gaps

While the majority of published research was observed in adults, systematic analyses covering this type of combination product reported patterns observed in older children as well. However, the data for certain groups remain insufficient. Major scientific reviews note that evidence is limited and certainty remains low for assessments in younger children (typically under 12 years of age). Findings were also mixed regarding patterns for specific individual cold symptoms, with reviews pointing to a lack of data for the fixed combination on all component symptoms when analyzed individually.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Febrilex (FAQ)

Q: What is the mechanism of action for the Chlorphenamine and Phenylephrine components?

Official product information describes that the Chlorphenamine component works by acting as an antihistamine, blocking certain histamine receptors to help relieve allergy-like symptoms. The Phenylephrine component acts on receptors to cause vasoconstriction, which is the narrowing of blood vessels, to help relieve nasal congestion.

Q: What happens if I forget to take a dose of Febrilex?

According to the official product instructions, if a dose is forgotten, it is important not to take a double dose to catch up. General patient information indicates that the guidance typically emphasizes respecting the required minimum time interval (such as four hours) before the next dose.

Q: How should I store Febrilex and where should I dispose of unused medicine?

Regulatory documents state that Febrilex must be stored at a temperature not exceeding 30 C and protected from light, kept in the original package, and out of the reach of children. For disposal, unused or expired product should not be thrown away in household waste or via wastewater. These disposal measures are required to help protect the environment, and advice should be sought from a pharmacist.

Q: What are the symptoms of a Febrilex overdose?

Symptoms of an overdose may appear within the first day and can include paleness, vomiting, loss of appetite, sweating, and abdominal pain. The most serious risk documented in regulatory information is the potential for severe liver damage (hepatotoxicity), which may lead to liver failure.

Q: Is it safe to drive after taking Febrilex?

Official product information advises using the medicine with caution because the antihistamine component, Chlorphenamine, commonly causes side effects such as drowsiness and dizziness. Regulatory warnings indicate that individuals should assess how the product affects them before engaging in tasks that require complete focus, such as driving or operating machinery.

How should Febrilex be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define specific, mandatory conditions for storing and disposing of Febrilex to maintain product quality and protect the environment.

Requirement Area	Official Instructions
Temperature & Light	Store at a temperature not exceeding 30 C and protected from light.
Packaging	Keep in the original package until the expiry date (shelf-life: 3 years). Do not use if there are visible signs of alteration.
Child Protection	Must be stored out of the sight and reach of children.
Disposal Rule	Do not throw away unused or expired product via wastewater or household waste.
Environmental Note	These disposal measures are required to help protect the environment; ask a pharmacist for disposal advice.

Storage above the mandated 30 C limit is prohibited. Following these steps ensures the medicine's stability and prevents environmental contamination.

Febrilex